Sabrina Serani - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Sabrina Serani's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Sabrina Serani
Verified
Senior Editor, Targeted Oncology
New York
Beats
Health , Environment , Science , Technology
Wine and spirits
Content
By Sabrina Serani Verified| Targeted Oncology Verified Iltamiocel, an investigational cell therapy, has been granted regenerative medicine advanced therapy (RMAT) designation by the FDA in patients with oropharyngeal dysphagia (OPD), a common complication following treatment for head and neck cancer. The autologous cell therapy is an in-office procedure being developed by Cook MyoSite Inc. and evaluated at UC Davis Health. Over 700 patients have been included in the therapy’s clinical development so far.
By Sabrina Serani Verified, Jordyn Sava Verified| Targeted Oncology Verified The FDA has approved the combination of sotorasib (Lumakras) and panitumumab (Vectibix) for the treatment of patients with previously treated KRAS G12C-mutated colorectal cancer (CRC). The approval is supported by data from the CodeBreaK 300 (NCT05198934) study. The combination led to improvements in progression-free survival (PFS) and overall response rate (ORR) vs investigator’s choice of standard of care.
By Sabrina Serani Verified| Targeted Oncology Verified Iltamiocel, an investigational cell therapy, has been granted regenerative medicine advanced therapy (RMAT) designation by the FDA in patients with oropharyngeal dysphagia (OPD), a common complication following treatment for head and neck cancer. The autologous cell therapy is an in-office procedure being developed by Cook MyoSite Inc. and evaluated at UC Davis Health. Over 700 patients have been included in the therapy’s clinical development so far.
Company Info
Targeted Oncology
Targeted Oncology is a key resource for oncology healthcare professionals, especially community oncologists. It provides valuable information on targeted therapies and immunotherapies in cancer treatment. As a brand under MJH Life Sciences, it is part of the largest privately held, independent medical media company in North America. The company offers a variety of services, including digital and print media that feature news and expert opinions on precision medicine in oncology. Targeted Oncology also hosts over 800 educational events each year, such as Case-Based Roundtable and Community Case Forum events, which facilitate networking and discussions among oncologists and hematologists. Additionally, it provides diverse content formats, including articles, videos, and podcasts, aimed at enhancing learning and practice outcomes in the field of oncology.
'+1 609-716-7777
Founded: 2012